FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2064246679> ?p ?o ?g. }

• W2064246679 endingPage "P205" @default.
• W2064246679 startingPage "P205" @default.
• W2064246679 abstract "This article was originally published online on 23 April 2013 We report the effective and safe use of subcutaneous immunoglobulin (SCIG) therapy in a patient who suffered stroke following replacement intravenous immunoglobulin (IVIG) infusions for common variable immune deficiency (CVID) at age 28 years. CVID is one of the 6 FDA-approved uses for IVIG, and is required lifelong in these patients. Systemic adverse reactions occur in approximately 2-6% of infusions 1, while thrombotic events are very rare. A Therapeutic dilemma arose when our patient had a stroke after an IVIG infusion. After the stroke, our patient’s IgG level fell to 1.17 g/L, resulting in recurrent pneumonia. Cautious doses of IVIG were restarted and the patient remained on warfarin. These were tolerated well for 13 years. With the introduction of higher concentrations of IgG available for subcutaneous administration, we transitioned the patient to SCIG since it offered many advantages. The preparation was tolerated well by the patient, resulted in therapeutic trough levels, and was effective at preventing infection. It is also associated with a lower risk of thrombotic complications including stroke theoretically since this is extremely rare, related to the even physiologic nature of serum IG levels, without marked increases in levels following the administration of the SCIG preparation 2. The patient was cautiously continued on IVIG therapy 7 months after the stroke, with modest doses initially of 20g in 250mL solution q4 weeks (goal trough IgG 5-7 g/L). This dose was effective and tolerated well and it was gradually titrated to higher trough levels 9 years later. With known and theoretical advantages of SCIG therapy, the patient achieved therapeutic trough IG level of 9.5 g/L, and did not have any further thrombotic events or other systemic reactions. The patient continues on q3-4-weekly SCIG infusions that are both safe and effective. This therapy may also offer significant Quality of life (QOL) advantages to the patients and their families. We report a CVID patient who had a cerebrovascular accident following an IVIG infusion. He was successfully restarted on IVIG therapy while on warfarin and then switched to SCIG, which he has tolerated well." @default.
• W2064246679 created "2016-06-24" @default.
• W2064246679 creator A5015724251 @default.
• W2064246679 creator A5057554383 @default.
• W2064246679 date "2013-01-01" @default.
• W2064246679 modified "2023-10-16" @default.
• W2064246679 title "Basic and clinical immunology – 3030. Subcutaneous immunoglobulin therapy: An option for patients who have experienced thrombotic complications with intravenous therapy" @default.
• W2064246679 doi "https://doi.org/10.1186/1939-4551-6-s1-p205" @default.
• W2064246679 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3643292" @default.
• W2064246679 hasPublicationYear "2013" @default.
• W2064246679 type Work @default.
• W2064246679 sameAs 2064246679 @default.
• W2064246679 citedByCount "0" @default.
• W2064246679 crossrefType "journal-article" @default.
• W2064246679 hasAuthorship W2064246679A5015724251 @default.
• W2064246679 hasAuthorship W2064246679A5057554383 @default.
• W2064246679 hasBestOaLocation W20642466791 @default.
• W2064246679 hasConcept C126322002 @default.
• W2064246679 hasConcept C127413603 @default.
• W2064246679 hasConcept C141071460 @default.
• W2064246679 hasConcept C159654299 @default.
• W2064246679 hasConcept C187212893 @default.
• W2064246679 hasConcept C197934379 @default.
• W2064246679 hasConcept C203014093 @default.
• W2064246679 hasConcept C2779352459 @default.
• W2064246679 hasConcept C2780645631 @default.
• W2064246679 hasConcept C2909916134 @default.
• W2064246679 hasConcept C2911027401 @default.
• W2064246679 hasConcept C71924100 @default.
• W2064246679 hasConcept C78519656 @default.
• W2064246679 hasConceptScore W2064246679C126322002 @default.
• W2064246679 hasConceptScore W2064246679C127413603 @default.
• W2064246679 hasConceptScore W2064246679C141071460 @default.
• W2064246679 hasConceptScore W2064246679C159654299 @default.
• W2064246679 hasConceptScore W2064246679C187212893 @default.
• W2064246679 hasConceptScore W2064246679C197934379 @default.
• W2064246679 hasConceptScore W2064246679C203014093 @default.
• W2064246679 hasConceptScore W2064246679C2779352459 @default.
• W2064246679 hasConceptScore W2064246679C2780645631 @default.
• W2064246679 hasConceptScore W2064246679C2909916134 @default.
• W2064246679 hasConceptScore W2064246679C2911027401 @default.
• W2064246679 hasConceptScore W2064246679C71924100 @default.
• W2064246679 hasConceptScore W2064246679C78519656 @default.
• W2064246679 hasLocation W20642466791 @default.
• W2064246679 hasLocation W20642466792 @default.
• W2064246679 hasLocation W20642466793 @default.
• W2064246679 hasOpenAccess W2064246679 @default.
• W2064246679 hasPrimaryLocation W20642466791 @default.
• W2064246679 hasRelatedWork W1510491287 @default.
• W2064246679 hasRelatedWork W2002120878 @default.
• W2064246679 hasRelatedWork W2028158554 @default.
• W2064246679 hasRelatedWork W2040149200 @default.
• W2064246679 hasRelatedWork W2047967234 @default.
• W2064246679 hasRelatedWork W2080265241 @default.
• W2064246679 hasRelatedWork W2396856814 @default.
• W2064246679 hasRelatedWork W2439875401 @default.
• W2064246679 hasRelatedWork W3032703025 @default.
• W2064246679 hasRelatedWork W4290695003 @default.
• W2064246679 hasVolume "6" @default.
• W2064246679 isParatext "false" @default.
• W2064246679 isRetracted "false" @default.
• W2064246679 magId "2064246679" @default.
• W2064246679 workType "article" @default.